Vitamin B12 for Canker Sores: RCT Evidence

Of all the nutritional interventions studied for recurrent canker sores (aphthous ulcers), vitamin B12 has the most compelling clinical trial evidence. A 2009 randomized double-blind placebo-controlled trial published in the Journal of the American Board of Family Medicine transformed how practitioners approach this common and frustrating condition. The study's most important finding was not merely that B12 helped patients who were deficient, but that it produced dramatic improvements regardless of baseline serum B12 levels, suggesting the mechanism goes beyond simple deficiency correction.

The Landmark RCT: Design and Findings

The trial enrolled 58 patients with recurrent aphthous stomatitis and randomized them to receive either sublingual vitamin B12 (1,000 mcg nightly) or placebo for six months. Patients tracked the number of ulcers, duration of outbreaks, and pain severity. At the end of the six months, the results were striking: the B12 group experienced a significantly greater reduction in number of outbreaks per month (dropping from approximately 3 to less than 1 in most patients), significantly fewer days with active ulcers per month, and dramatically lower pain scores during outbreaks. The placebo group showed only modest spontaneous improvement. Most remarkably, the benefit was observed across all patients in the B12 group, not just those who entered the study with low serum cobalamin levels. Patients with normal baseline B12 responded just as well as those with borderline deficiency.

Why Does B12 Help Even Without Deficiency?

This paradox, B12 helping canker sores even in people with adequate serum levels, has generated interesting hypotheses. One is that serum B12 is an imperfect proxy for cellular or tissue-level B12 sufficiency. Methylmalonic acid (MMA) and homocysteine are more sensitive functional markers that can be elevated even when serum B12 appears normal. It is possible that patients who appear B12-sufficient by serum measurement have functional insufficiency detectable with more sensitive tests.

A second hypothesis involves B12's regulatory role in the immune response. Methylcobalamin specifically influences cytokine profiles, shifting T-cell activity in ways that reduce the inflammatory infiltrate responsible for aphthous ulcer formation. Animal studies have shown that B12 modulates Th1/Th2 balance and reduces production of pro-inflammatory cytokines like interferon-gamma and TNF-alpha in mucosal tissue, effects that do not require frank deficiency to be pharmacologically relevant at supraphysiological doses.

A third possibility is that high-dose sublingual B12 exerts local effects on oral mucosal cells by being absorbed through the sublingual mucosa before passing through the liver, achieving higher local tissue concentrations than oral ingestion would produce.

Methylcobalamin vs. Cyanocobalamin

The study used a proprietary sublingual preparation, and most researchers recommend methylcobalamin specifically for this indication rather than cyanocobalamin. Methylcobalamin is the neurologically active form of B12 that participates directly in methyl group transfer reactions without requiring conversion. It also has a longer plasma half-life and may be preferentially retained in neural and mucosal tissues. Cyanocobalamin requires conversion to methylcobalamin (and adenosylcobalamin) before use and generates a small amount of cyanide as a byproduct, though this is physiologically insignificant at standard doses. Sublingual methylcobalamin dissolves under the tongue, bypassing the need for intrinsic factor-dependent absorption in the gut, which is particularly important for elderly patients and those with gastric atrophy or prior bariatric surgery who have impaired B12 absorption.

Replication and Current Evidence Status

The 2009 trial has not yet been replicated in a large multi-center study, which is the gold standard for establishing treatment efficacy. However, smaller studies and case series support the finding, and a systematic review of nutritional deficiencies in recurrent aphthous stomatitis consistently identifies B12 as the most common and most tractable deficiency. Given the excellent safety profile of sublingual B12 at 1,000 mcg, the cost-benefit ratio of a therapeutic trial is highly favorable, even before confirmatory large trials are available.

Practical Protocol

Based on the RCT, the protocol is simple: 1,000 mcg of sublingual methylcobalamin nightly for at least 6 months. The tablet should be placed under the tongue and allowed to dissolve fully (2-3 minutes) before swallowing. Patients in the trial noticed reductions in outbreak frequency within the first 1-2 months. No serious adverse effects have been associated with this dose. B12 is water-soluble and excess is excreted in urine, making toxicity essentially impossible at supplemental doses.

Screening for Underlying Deficiency

Even though the B12 intervention works regardless of serum levels, baseline testing with serum B12, methylmalonic acid, and homocysteine is reasonable to identify patients with true deficiency who may need higher doses or injectable B12 to fully replenish stores. Vegans and vegetarians, elderly adults with reduced stomach acid, individuals with Crohn's disease or celiac disease, and those taking long-term metformin or proton pump inhibitors are at elevated risk for true B12 deficiency and may warrant more aggressive assessment and treatment.

FAQ

Q: How long does it take for B12 to reduce canker sores?

The RCT showed progressive improvement over the 6-month treatment period, with most patients experiencing significant reductions within 2-3 months. Complete remission (no outbreaks for the final month of the trial) was achieved by a substantial proportion of the B12 group.

Q: Should I get tested for B12 deficiency before starting supplementation?

Testing is useful for identifying true deficiency requiring more intensive treatment, but is not required before starting sublingual B12. Given the safety of B12 supplementation, starting a trial is reasonable while testing results are pending.

Q: Does B12 help with cold sores (herpes labialis) too?

B12 is studied primarily for aphthous ulcers (canker sores), which are NOT caused by the herpes virus. Cold sores are herpes simplex virus outbreaks and require different treatment. Do not confuse the two, as their causes and management differ significantly.

Track your supplements in Optimize.